Le Lézard
Classified in: Health
Subject: SVY

Global Allergy Immunotherapies Markets, 2018-2019 & 2024: Demand for Sophisticated and Long-Term Treatment Options is Increasing


DUBLIN, Aug. 23, 2019 /PRNewswire/ -- The "Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global allergy immunotherapies market was worth US$ 1.6 Billion in 2018

Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a preventive medical treatment for allergic reactions to allergens including various foods, drugs, bee venom, grass pollens and house dust mites. It alters the immune system's response by gradually increasing the doses of the allergen.

Before the treatment begins, an allergist and patient analyze triggering factors for allergy symptoms, which may involve skin and blood tests to confirm the allergens. Allergy immunotherapy helps in reducing inflammation, offering long-term impact, increasing immunological tolerance, changing the course of the disease and improving the quality of the patient's life.

In recent years, there has been a rise in the prevalence of allergies around the world on account of various environmental and lifestyle factors that influence the functioning of the immune system. With the growing awareness of allergy immunotherapies, elevating income levels and increasing healthcare expenditure, the demand for sophisticated and long-term treatment options is increasing, which in turn is stimulating the growth of the market. It is further supported by the rising clinical research and development budget owing to several initiatives undertaken by both governmental and non-governmental organizations around the world.

Further, with the latest drug development technologies, pharmaceutical firms have created more efficient immunotherapies for treating an array of allergies successfully. This, coupled with advancements in the field of allergy diagnostics, is catalyzing the global allergy immunotherapies market growth.

Looking forward, the market to reach a value of US$ 2.4 Billion by 2024, registering a CAGR of around 7% during 2019-2024.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Allergy Immunotherapies Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Treatment Type
5.4 Market Breakup by Allergy Type
5.5 Market Breakup by Distribution Channel
5.6 Market Breakup by Region
5.7 Market Forecast

6 Market Breakup by Treatment Type
6.1 Subcutaneous Immunotherapy (SCIT)
6.2 Sublingual Immunotherapy (SLIT)

7 Market Breakup by Allergy Type
7.1 Allergic Rhinitis
7.2 Asthma
7.3 Food Allergy
7.4 Venom Allergy
7.5 Others

8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacy
8.2 Retail Pharmacy
8.3 Online Pharmacy

9 Market Breakup by Region

10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis
13.1 Price Indicators
13.2 Price Structure
13.3 Margin Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 ALK-Abello A/S
14.3.2 Allergy Therapeutics
14.3.3 Stallergenes Greer
14.3.4 HAL Allergy Group
14.3.5 DBV Technologies
14.3.6 Merck Group
14.3.7 Aimmune Therapeutics
14.3.8 Circassia Pharmaceuticals
14.3.9 Anergis SA
14.3.10 Biomay AG

For more information about this report visit https://www.researchandmarkets.com/r/oqvzeb

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: